Subclinical Atrial Fibrillation Prediction in Patients with CIED by a Novel Deep Learning Framework.
Source check: Source checked. Not independent scientific confirmation.
Finding / tested result: ResKAN-Attention predicted device-detected subclinical AF in a retrospective cohort of 124 pacemaker patients, with five-fold CV AUC 0.837 and AUC 0.788 in a separately enrolled prospective 35-patient cohort. This is a small single-center validation, not evidence of clinical utility.
Technology: Dual-path KAN/MLP with cross-attention trained on 27 routine features, with preprocessing fit inside folds and SMOTE restricted to training data. Primary retrospective cohort 124 patients; separate prospective 35 patients with six-month monitoring for external validation; AUC 0.788.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Dual-path KAN/MLP with cross-attention trained on 27 routine features, with preprocessing fit inside folds and SMOTE restricted to training data. Primary retrospective cohort 124 patients; separate prospective 35 patients with six-month monitoring for external validation; AUC 0.788.
- Limitation / still unknown
- ResKAN-Attention predicted device-detected subclinical AF in a retrospective cohort of 124 pacemaker patients, with five-fold CV AUC 0.837 and AUC 0.788 in a separately enrolled prospective 35-patient cohort. This is a small single-center validation, not evidence of clinical utility.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://mdpi-res.com/d_attachment/jcdd/jcdd-13-00018/article_deploy/jcdd-13-00018.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.